Retinoids and ovarian cancer

Journal of Cellular Physiology

Volumn 185, Issue 1, 2000, Pages 1-20

  Zhang, Dongmei ^a   Holmes, William F ^a   Wu, Shujian ^a   Soprano, Dianne R ^a   Soprano, Kenneth J ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FENRETINIDE; ISOTRETINOIN; ONCOPROTEIN; RAS PROTEIN; RETINOIC ACID; RETINOID; RETINOL;

CANCER CLASSIFICATION; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; EARLY DIAGNOSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE MYC; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; FEMALE; FENRETINIDE; HUMANS; OVARIAN NEOPLASMS; RETINOIDS;

EID: 0033849372     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O     Document Type: Review

References (250)

1. Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma cells involves caspase-dependent and independent pathways
2. Molecular cloning of two human cellular retinoic acid-binding proteins (CRABP)
3. The biology of ovarian cancer
4. Purification and partial characterization of a novel binding protein for retinoic acid from neonatal rat
5. The neu oncogene encodes an epidermal growth factor receptor-related protein
6. Use of high dose cis-dichlorodiammine platinum (II) (NSC-119875) following failure on previous chemotherapy for advanced carcinoma of the ovary
7. Cell growth regulation in epithelial ovarian cancer
8. Molecular approaches to prevention and detection of epithelial ovarian cancer
9. Regulation of the retinoblastoma protein-related p107 by G1 cyclin complexes
10. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo
11. The performance of screening tests for ovarian cancer: Results of a systematic review
12. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
13. A new retinoic acid receptor identified from a hepatocellular carcinoma
14. Biomarkers in the Ovary
15. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer
16. DNA binding specificity of steroid receptors
17. Identification of synthetic retinoids with selectivity for human nuclear retinoic acid receptor gamma
18. p27Kip1 accumulation is associated with retinoic-induced neuroblastoma differentiation: Evidence of a decreased proteasome-dependent degradation
19. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha
20. The level of CRABP-I expression influences the amounts and types of all-trans retinoic acid metabolites in F9 teratocarcinoma cells
21. Identification of a second human retinoic acid receptor
22. Effect of differentiation agents on expression of CA 125, alkaline phosphatase, and cytokeratins in human ovarian adeno-carcinoma cells (OVCA 433)
23. RXR- , a promiscuous partner of retinoic acid and thyroid hormone receptors
24. Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: Relationship with induction of differentiation and retinoic acid receptor expression
25. Independent binding of the retinoblastoma protein and p107 to the transcription factor E2F
26. Role of CBP/P300 in nuclear receptor signalling
27. A decade of molecular biology of retinoic acid receptors
28. Effects of receptor class- and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH:OVCAR-3 ovarian cancer cell line in culture
29. Transformation mediated by the human HER-2 gene independent of the epidermal GF receptor
30. The E2F transcription factor is a cellular target for the RB protein
31. A transcriptional co-repressor that interacts with nuclear hormone receptors
32. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1)
33. Cellular retinoid-binding proteins
34. Functional analysis of pRb2/p130 interaction with cyclins
35. Cell cycle-specific association of E2F with the p130 E1A-binding protein
36. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients
37. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide
38. Epidemiology and risk assessment for ovarian cancer
39. The relationship of serum vitamin A, cholesterol, and triglycerides to the incidence of ovarian cancer
40. Risks and benefits of retinoids in the chemoprevention of cancer
41. Identification of a retinoic acid-responsive element in the retinoic acid receptor β gene
42. Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2
43. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
44. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
45. Differential expression of genes encoding α, β and γ retinoic acid receptors and CRABP on the developing limbs of the mouse
46. All-trans and 9-cis retinoic acid induction of CRABP-II promoter is activated by an RAR/RXR heterodimers bound to DR1 and DR2 repeated motifs
47. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit
48. The regulation of E2F by pRB-family proteins
49. Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families. The Breast Cancer Linkage Consortium
50. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium
51. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma
52. The steroid and thyroid hormone receptor superfamily
53. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein
54. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors
55. Chromatin unfolds
56. The three members of the pocket proteins family share the ability to repress E2F activity through recruitment of a histone deacetylase
57. Expression ofcellular retinoic acid binding protein (CRABP) in E. Coli
58. Prognostic factors in ovarian cancer
59. Unusual proliferation arrest and transcriptiopal control properties of a newly discovered E2F family member, E2F-6
60. Etiology of ovarian cancer: A proposed mechanism
61. Molecular cloning of cDNA encoding a second cellular retinoid acid binding protein
62. Identification of a receptor for the morphogen retinoic acid
63. Structural motif of-lactoglobulin and retinol binding proteins: A basic framework for binding and transporting a small hydrophobic molecules?
64. A clinical trial of beta carotene to prevent basal-cell and squamous-cell cancers of the skin. The Skin Cancer Prevention Study Group
65. The differential effects of N,N-dimethylformamide and transforming growth factor-beta 1 on a human ovarian cancer cell line (HOC-7)
66. Comparative analysis of the effects of dimethyl sulfoxide and retinoic acid on the antigenic pattern of human ovarian adenocarcinoma cells
67. The effects of dimethyl sulfoxide and retinoic acid on the cell growth and the phenotype of ovarian cancer cells
68. Linkage of early-onset familial breast cancer to chromosome 17q21
69. Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent
70. A prospective study of reproductive factors and risk of epithelial ovarian cancer
71. Isolation of the Rb-related p130 through its interaction with CDK2 and cyclins
72. p300 is a component of an estrogen receptor coactivator complex
73. Retinoic acid receptors in retinoid responsive ovarian cancer cell lines detected by polymerase chain reaction following reverse transcription
74. Regulation of interleukin-8 gene expression by all-trans retinoic acid
75. Perineal exposure to talc and ovarian cancer risk
76. Rates and risks of ovarian cancer in subgroups of white women in the United States. The Collaborative Ovarian Cancer Group
77. Serum levels of vitamins A and E in women with ovarian cancer
78. Serum vitamins A and E and carotene in patients with gynecologic cancer
79. Regulation of cell proliferation by the E2F transcription factors
80. A cDNA encoding a pRB-binding protein With properties of the transcription factor E2F
81. Serum gonadotropins and steroid hormones and the development of ovarian cancer
82. Prospective study of serum micronutrients and ovarian cancer
83. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study
84. Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: An immunohistochemical study
85. E2F-5, a new E2F family member that interacts with p130 in vivo
86. 13-cis-retinoic acid in the treatment of oral leukoplakia
87. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
88. Prospective on ovarian cancer: Why prevent?
89. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway
90. The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations
91. Increased expression of the putative growth factor receptor p185(HER-2) causes transformation and tumorigenesis of NIH3T3 cells
92. Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F
93. The clonal orgin of ovarian cancer: Analysis by loss of heterozygosity, p53 mutation hand X chromosome inactivation
94. Possible role of retinoic acid binding protein in retinoid stimulation of embryonal carcinoma cell differentiation
95. Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-binding domain in the retinoblastoma gene product
96. Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties
97. Reduction of retinaldehyde bound to cellular retinol-binding protein (type II) by microsomes from rat small intestine
98. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
99. Murine isoforms of retinoic acid receptor with specific patterns of expression
100. Influence of retinol nutritional status on cellular retinol and cellular retinoic acid-binding concentrations in various rat tissues
101. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients
102. Distinct roles of the co-activators p300 and CBP in retinoic-acid- induced F9-cell differentiation
103. Characterization of an established cell line from human immature teratoma of the ovary and effects of retinoic acid on cell proliferation
104. 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway
105. Retinoid X receptor-COUP-TF interactions modulate retinoic acid signaling
106. Convergence of 9-cis-retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
107. Protein motifs 5. Zinc fingers
108. Antioncogenes and human cancer
109. Genetics of human cancer
110. Mutation and cancer: Statistical study of retinoblastoma
111. Retinoic acid induced death of ovarian carcinoma cells correlates with c-myc stimulation
112. A third human retinoic acid receptor, hRAR-gamma
113. Polarity-specific activities of retinoic acid receptors determined by a co-repressor
114. Analysis of the ligand-binding domain of human retinoic acid receptor alpha by site-directed mutagenesis
115. Cancer statistics, 1998
116. Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines
117. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo
118. Posttranslational regulation of cyclin D1 by retinoic acid: A chemoprevention mechanism
119. The influence of a hyper-vitaminosis on the effect of 20-methylcholanthrene on mouse prostate glands growth in vitro
120. The retinoblastoma protein binds to a family of E2F transcription factors
121. Multiplicity generates diversity in the retinoic acid signalling pathways
122. Mouse retinoic acid receptor 2 isoform is transcribed from a promoter that contains a retinoic acid response element
123. The effect of retinoic acid on chemosensitivity of PA-1 human teratocarcinoma cells and its modulation by an activated N-ras oncogene
124. Rat cellular retinol-binding protein II: Use of a cloned cDNA to define its primary structure, tissue specific expression and developmental regulation
125. The adenovirus E1A-associated 130-kD protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E
126. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines
127. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis
128. Retinoids and chemoprevention: Clinical and basic studies
129. Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation
130. Specific enzymatic dephosphorylation of the retinoblastoma protein
131. Rb interacts with histone deacetylase to repress transcription
132. Genetics and ovarian carcinoma
133. Retinoblastoma protein represses transcription by recruiting a histone deacetylase
134. Characterization of three RXR genes that mediate the action of 9-cis retinoic acid
135. Nuclear receptor that identifies a novel retinoic acid response pathway
136. The retinoid receptors
137. A direct repeat in the cellular retinol binding protein type II gene confers differential regulation by RXR and RAR
138. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxy-phenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus
139. Effects of biological response modifiers on ovarian carcinoma cell lines
140. p27Kip1: A key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line
141. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)-retinamide in neuroblastoma cell lines
142. pRB, p107 and p130 as transcriptional regulators: Role in cell growth and differentiation
143. Cloning of a new member of the retinoblastoma gene family (pRb2) which binds to the E1A transforming domain
144. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
145. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: A randomized trial
146. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
147. Regression of bronchial epidermoid metaplasia in heavy smokers with etretinate treatment
148. Control of pRB phosphorylation
149. Unifocal origin of advanced human epithelial ovarian cancer
150. Retinoids in prevention of skin cancer
151. Segregation of retinoic acid effects on fetal ovarian germ cell mitosis versus apoptosis by requirement for new macromolecular synthesis
152. An E2F-like repressor of transcription
153. Vitamin A transport in rat plasm: Isolation and characterization of retinol-binding protein
154. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional response to three nuclear receptors
155. Retinoicacid prevents phosphorylation of pRB in normal human B lymphocytes: Regulation of cyclin E, cyclin A, and p21(Cip1)
156. RAR-β4, a retinoic acid receptor isoform is generated from RAR-β2 by alternative splicing and usage of a CUG initiator codon
157. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
158. Familial breast-ovarian cancer locus on chromosome 17q12-q23
159. Advances in the chemotherapy of gynecologic cancer
160. Toward an understanding of the functional complexity of the E2F and retinoblastoma families
161. Vitamin A
162. Radioimmunochemical determination of cellular retinol- and cellular retinoic acid-binding proteins in cytosols of rat tissues
163. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells
164. The N-terminal portion of domain E of retinoic acid receptors alpha and beta is essential for the recognition of retinoic acid and various analogs
165. Serine 232 and methionine 272 define the ligand binding pocket in retinoic acid receptor subtypes
166. Retinoblastoma protein family in cell cycle and cancer: A review
167. Adjuvant treatment of stage I lung cancer with high-dose vitamin A
168. Determinants for selective RAR and TR recognition of direct repeat HREs
169. Regulation of gene expression by vitamin A: The role of nuclear retinoic acid receptors
170. A human retinoic acid receptor which belongs to the family of nuclear receptors
171. Localization of cellular retinol-binding protein in several rat tissues
172. Ordered binding of etinoic acid and retinoid X receptors to asymmetric response elements involves determinants adjacent to the DNA-binding domain
173. Crystal structure of the RAR-gamma ligand-binding domain bound to all- trans retinoic acid
174. Pelvic inflammatory disease and the risk of epithelial ovarian cancer
175. Estrogen replacement therapy and fatal ovarian cancer
176. Ovarian tumors in a cohort of infertile women
177. A member of the RXR nuclear receptor family is expressed in neural-crest-derived cells of the developing chick peripheral nervous system
178. Paclitaxel (taxol)
179. Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor Alpha (RARAlpha)-, RAR-Beta-, or RARgamma-selective ligand in combination with a retinoid X receptor-specific ligand
180. Specific spatial and temporal distribution of retinoic acid receptor gamma transcripts during embryogenesis
181. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide
182. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25- dihydroxyvitamin D3, retinoic acid and dexamethasone
183. Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone
184. Differential role of homologous positively charged amino acid residues for ligand binding in retinoic acid receptor alpha compared with retinoic acid receptor beta
185. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: Correlation with clinical outcome and response to chemotherapy
186. Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues. Correlation with histopathologic features and receptors for estrogen, progesterone, and epidermal growth factor receptor
187. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo
188. Identification of two candidate tumor suppressor genes on chromosome 17p13.3
189. Association of BRCA1 with Rad51 in mitotic and meiotic cells
190. Dysregulated expression of cyclin D1 in normal human mammary epithelial cells inhibits all-trans-retinoic acid-mediated G0/G1-phase arrest and differentiation in vitro
191. p53 Independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells
192. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2
193. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner
194. Molecular cloning and analysis of functional cDNA and genomic clones encoding bovine cellular retinoic acid binding protein
195. Activity of the retinoblastoma family proteins, pRB, p107, and p130, during cellular proliferation and differentiation
196. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
197. Distinct mechanisms control the accumulation of the Rb-related p107 and p130 proteins during cell growth
198. Relationship of myc protein expression to the phenotype and to the growth potential of HOC-7 ovarian cancer cells
199. Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition
200. Retinoic acid promotes ubiquitination and proteolysis of cyclin D1 during induced tumor cell differentiation
201. Response of oral leukoplakias to the administration of vitamin A
202. Characterization of an utoregulated response element in the mouse retinoic acid receptor type β gene
203. Posttranslational mechanisms contribute to the suppression of specific cyclin: CDK complexes by all-trans retinoic acid in human bronchial epithelial cells
204. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437
205. Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression
206. Modulation of differentiation in PA-1 human teratocarcinoma cells after N-ras oncogene-induced tumorigenicity
207. Arg269 and Lys220 of retinoic acid receptor-beta are important for the binding of retinoic acid
208. Alteration in the retinoid specificity of retinoic acid receptor-Beta by site-directed mutagenesis of Arg269 and Lys220
209. Cell-type and promoter-context dependent retinoic acid receptor (RAR) redundancies for RAR beta 2 and Hoxa-1 activation in F9 and P19 cells can be artefactually generated by gene knockouts
210. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: A multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group
211. c-myc Over-expression in human primary ovarian tumours: Its relevance to tumour progression
212. Alterations of cellular characteristics of a human ovarian teratocarcinoma cell line after in vitro treatment with retinoids
213. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells
214. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage
215. The molecular basis of ovarian cell death during germ cell attrition, follicular atresia, and luteolysis
216. The epidemiology of ovarian cancer
217. E2F-6, a member of the E2F family that can behave as a transcriptional repressor
218. Determinants of target gene specificity for steroid/thyroid hormone receptors
219. Retinoic acid and thyroid hormone induce gene expression through a common responsive element
220. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study
221. pRb phosphorylation is regulated differentially by cyclin-dependent kinase (Cdk) 2 and Cdk4 in retinoic acid-induced neuronal differentiation of P19 cells
222. Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression
223. Cellular retinoic acid and cellular retinol-binding proteins: Complementary deoxyibonucleic acid cloning, chromosomal assignment and tissue specific expression
224. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer
225. Association between an oncogene and an anti-oncogene: The adenovirus E1A proteins bind to the retinoblastoma gene product
226. c-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of p185(c-erbB-2)-overexpressing ovarian carcinoma cells
227. Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells
228. Nutrition Classics
229. Tissue changes following deprivation of fat-soluble A vitamin
230. Histone deacetylase: A regulator of transcription
231. Identification of sulfnydryl-modified cysteine residues in the ligand binding pocket of retinoic acid receptor beta
232. Identification of the breast cancer susceptibility gene BRCA2
233. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13
234. All-trans-retinoic acid blocks cell cycle progression of human ovarian adenocarcinoma cells at late G1
235. Reduction of both RAR and RXR levels is required to maximally alter sensitivity of CA-OV3 ovarian tumor cells to growth suppression by all- trans-retinoic acid
236. Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth
237. Critical role of both retinoid nuclear receptors and retinoid-X- receptors in mediating growth inhibition of ovarian cancer cells by all- trans retinoic acid
238. A canonical structure for the ligand-binding domain of nuclear receptors
239. Biochemical characteristics of isolated rat liver stellate cells
240. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer
241. RXR-β: A coregulator that enhaces binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements
242. Retinoic acid-mediated growth arrest of EBV-immortalized B lymphocytes is associated with multiple changes in G1 regulatory proteins: p27Kip1 up-regulation is a relevant early event
243. Cloning of murine and retinoic acid receptor and a novel receptor gamma predominately expressed in skin
244. Retinoid X receptor is an auxilliary protein for thyroid hormone and retinoid acid receptors
245. Homodimer formation of retinoid X receptor induced by 9-cis retinoic acid
246. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model
247. Arg278, but not Lys229 or Lys236, plays an important role in the binding of retinoic acid by retinoic acid receptor gamma
248. Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitro
249. Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer